Trevena, Inc.

Equities

TRVN

US89532E2081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.391 ^USD	-4.40%		+11.08%	-45.85%

Apr. 01	Trevena, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 01	Trevena, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Trevena Inc. Receives OLINVYK Agreement with Premier, Inc

December 04, 2023 at 07:00 am EST

Trevena Inc. announced that it has been awarded a national group purchasing agreement for OLINVYK with Premier Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK.

Latest news about Trevena, Inc.

Trevena, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Trevena, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer	Feb. 01	CI
Trevena Raises $4 Million via Placement, Warrant Exercise	Dec. 28	MT
Trevena, Inc. announced that it has received $1.945934 million in funding	Dec. 27	CI
Trevena to Raise $4 Million From Private Placement, Warrants Exercise Agreements	Dec. 27	MT
Trevena, Inc. announced that it expects to receive $1.945934 million in funding	Dec. 26	CI
Trevena Inc. Receives OLINVYK Agreement with Premier, Inc	Dec. 04	CI
Trevena Files $200 Million Mixed Shelf	Dec. 04	MT
Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries	Nov. 30	CI
Transcript : Trevena, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Trevena, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (TRVN) TREVENA Posts Q3 Revenue $180,000	Nov. 14	MT
North American Morning Briefing : Caution -2-	Nov. 14	DJ
Trevena, Inc. Announces Board Changes	Nov. 09	CI
Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study	23-10-02	CI
Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023	23-09-18	CI
Transcript : Trevena, Inc. - Special Call	23-09-06
Top Premarket Gainers	23-09-06	MT
Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement	23-09-06	CI
Trevena, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Earnings Flash (TRVN) TREVENA Reports Q2 Revenue $3M	23-08-14	MT
Trevena, Inc. Appoints Mark Corrigan to Board of Directors	23-07-20	CI
Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study	23-06-26	CI
Expected House Vote on Debt Ceiling Deal Weighs on Sentiment, Pushing US Equity Futures Lower	23-05-31	MT

Chart Trevena, Inc.

Duration

Period

More charts

Company Profile

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companyâs pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.391 USD

Average target price

6 USD

Spread / Average Target

+1,434.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TREVENA, INC.	-45.85%	7.16M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs